Latest Breaking News On - Marisol peron - Page 3 : comparemela.com

Genmab Announces Financial Results for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Andrew carlsenMarisol peronJanssen biotech incSeagen incProfoundbio incDrug administrationAbbvie biotechnology ltdGlobal communications corporate affairsAbbvie incExchange commissionPfizer incAnnounces financial resultsFirst quarterFirst quarter ended marchPriority reviewBiologics license application

TIVDAK® (tisotumab vedotin-tftv) Receives U S FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin-tftv) Receives U S FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Miami beachNew jerseyUnited statesAndrew carlsenMarisol peronBrian slomovitzChris boshoffTamika felderEuropean society of medical oncologyGynecologic oncology groupAmerican cancer societyNational cancer instituteGlobal communications corporate affairsCervivor incCompany announcementPfizer inc

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program Genmab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesMarisol peronAndrew carlsenCompany anouncementCompany announcementGlobal communications corporate affairsCommission delegated regulationExchange commissionHarbour regulationSenior vice presidentGlobal communicationsVice presidentAnnual reportY shaped genmabJacobsens vej

TIVDAK® (tisotumab vedotin-tftv) Receives U S FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient.

Miami beachNew jerseyUnited statesChris boshoffBrian slomovitzTamika felderMarisol peronAndrew carlsenExchange commissionNational cancer institutePfizer incGlobal communications corporate affairsAmerican society of clinical oncologyDrug administrationCervivor incGynecologic oncology group

Genmab A/S: TIVDAK (tisotumab vedotin-tftv) Receives U S FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S: TIVDAK (tisotumab vedotin-tftv) Receives U S FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Miami beachNew jerseyUnited statesMarisol peronDennis riedlTamika felderAndrew carlsenBrian slomovitzChris boshoffEuropean network of gynaecological oncological trial groupsPfizer incAmerican cancer societyGynecologic oncology groupExchange commissionAmerican society of clinical oncologyCervivor inc